Pharmacologic consideration for the use of antiretroviral agents in the elderly (Q37277510)

19 August 2017

1 reference

title

Pharmacologic consideration for the use of antiretroviral agents in the elderly (English)

1 reference

19 August 2017

anti-retroviral agent

0 references

1 reference

2

David J Greenblatt

1 reference

19 August 2017

Martin S Rhee

1

1 reference

19 August 2017

1 October 2008

1 reference

The Journal of Clinical Pharmacology

19 August 2017

1 reference

19 August 2017

48

1 reference

19 August 2017

10

1 reference

19 August 2017

1212-1225

1 reference

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

19 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

AIDS in the elderly: New York City vital statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Survival trends for patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Older age and the response to and tolerability of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Drug interactions between antiretroviral drugs and comedicated agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Drug interactions in the management of HIV infection: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Interactions among drugs for HIV and opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Impact of Various Antiretroviral Drugs and Their Plasma Concentrations on Plasma Lipids in Heavily Pretreated HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Biologic effects and safety of stavudine: overview of phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Protein binding in antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

The effect of age upon liver volume and apparent liver blood flow in healthy man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Liver function and phase I drug metabolism in the elderly: a paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Effect of age and gender on the activity of human hepatic CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

The influence of age and sex on the clearance of cytochrome P450 3A substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008322177

21 January 2018

Identifiers

DOI

10.1177/0091270008322177

1 reference

19 August 2017

1 reference

PubMed ID

18812611